预期应用
ELISA法定量测定人血清、血浆、细胞培养物上清或其它相关液体中骨保护素含量。
实验原理
本试剂盒应用双抗体夹心酶标免疫分析法测定标本中骨保护素水平。用纯化的抗体包被微孔板，制成固相抗体，往包被单抗的微孔中依次加入骨保护素、生物素化的抗人骨保护素抗体、HRP标记的亲和素，经过彻底洗涤后用底物TMB显色。TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的骨保护素呈正相关。用酶标仪在450nm波长下测定吸光度（OD值），计算样品浓度。
Intended use
This immunoassay kit allows for the specific measurement of human s Osteoprotegerin (OPG) concentrations in cell culture supernates, serum, and plasma.
Introduction
Osteoprotegerin, also known as osteoclastogenesis inhibitory factor (OCIF), is a cytokine and a member of the tumor necrosis factor (TNF) receptor superfamily. It is a basic glycoprotein comprising 401 amino acid residues arranged into 7 structural domains. It is found as either a 60 kDa monomer or 120 kDa dimer linked by disulfide bonds.Osteoprotegerin inhibits the differentiation of macrophages into osteoclasts and also regulates the resorption of osteoclasts in vitro and in vivo. Osteoprotegerin is a RANK homolog, and works by binding to RANK ligand on osteoblast/stromal cells, thus blocking the RANK-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast. Recombinant human osteoprotegerin specifically acts on bone, increasing bone mineral density and bone volume. Osteoprotegerin has been used experimentally to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases.
Osteoprotegerin production is stimulated in vivo by the female sex hormone estrogen,as well as the experimental osteoporosis drug, strontium ranelate.
Test principle
This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for Osteoprotegerin has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any Osteoprotegerin present is bound by the immobilized antibody. An enzyme-linked monoclonal antibody specific for Osteoprotegerin is added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Osteoprotegerin bound in the initial step. The color development is stopped and the intensity of the color is measured.
| 
